New challenges and inspired answers for anticancer drug discovery and development

Japanese Journal of Clinical Oncology

Volumn 43, Issue 10, 2013, Pages 945-953

  Utsugi, Teruhiro ^a  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Breast medicine; GI medicine; Immunology; Lung Med; New technology instruments

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; ENZYME INHIBITOR; FLUOROPYRIMIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GIMERACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OTERACIL; OXALIPLATIN; PACLITAXEL; PLACEBO; PYRIMIDINE DERIVATIVE; TAS 102; TAS 114; TAS 115; TAS 116; TAS 117; TAS 2104; TAS 2913; TAS 2985; TEGAFUR; THYMIDINE PHOSPHORYLASE INHIBITOR; TRIFLURIDINE; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CARDIOTOXICITY; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; HAND FOOT SYNDROME; HUMAN; LACRIMAL DUCT OCCLUSION; LIVER CANCER; LUNG NON SMALL CELL CANCER; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; NEUROTOXICITY; NONHUMAN; PANCREAS CANCER; PHYSICAL CHEMISTRY; STOMACH CANCER; STOMATITIS;

BREAST MEDICINE; GI MEDICINE; IMMUNOLOGY; LUNG-MED; NEW TECHNOLOGY/INSTRUMENTS;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DNA, NEOPLASM; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; HUMANS; MOLECULAR TARGETED THERAPY; PYRIMIDINES;

EID: 84885101279     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt131     Document Type: Article

References (37)

1. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
2. Fujii S, Ikenaka K, Fukushima M, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2- tetrahydrofuryl)-5-fluorouracil. Gann 1978;69:763-72.
3. Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. J Clin Oncol 1998;16:2877-85.
4. Omura K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol 2003;8:132-8.
5. Lembersky BC,Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from national surgical adjuvant breast and bowel project protocol C-06. J Clin Oncol 2006;24:2059-64.
6. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-21.
7. Nakajima T, Kinoshita T, Nashimoto A, et al. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007;94:1468-76.
8. Shirasaka T, Nakano K, Takechi T, et al. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602-6.
9. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-21.
10. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-20.
11. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-93.
12. Okamoto I, Yoshioka H, Morita S, et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapynaïve patients with advanced Non-small-cell lung cancer: results of a west japan oncology group study. J Clin Oncol 2010;28:5240-6.
13. Muro K, Boku N, Shimada Y, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomized phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010;11:853-60.
14. Gadsden MH, McIntosh EM, Game JC, Wilson PJ, Haynes RH. dUTP pyrophosphatase is an essential enzyme in Saccharomyces cerevisiae. EMBO J 1993;12:4425-31.
15. Ladner RD, Lynch FJ, Groshen S, et al. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. Cancer Res 2000;60:3493-503.
16. Nobili S, Napoli C, Landini I, et al. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer. Int J Cancer 2011;128:1935-45.
17. Yano W, Yokogawa T, Fukuoka M, et al. In vitro characterization of a novel dUTPase inhibitor, TAS-114, as a fluoropyrimidine enhancer. In: 24th EORTC-NCI-AACR symposium 2012 (Abstract 67).
18. Yokogawa T,Wakasa T, YanoW, et al. TAS-114 enhances S-1 activity in vivo when used in combination. In: 24th EORTC-NCI-AACR symposium 2012 (Abstract 65).
19. Wakasa T, Yamamura K, Tsuji S, et al. TAS-114 in combination, with capecitabine-based chemotherapy may represent a novel therapeutic strategy. In: 24th EORTC-NCI-AACR symposium 2012 (Abstract 68).
20. Emura T, Nakagawa F, Fujioka A, et al. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med 2004;13: 249-55.
21. Langenbach RJ, Danenberg PV, Heidelberger C. Thymidylate synthetase: mechanism of inhibition by 5-fluoro-20-deoxyuridylate. Biochem Biophys Res Commun 1972;48:1565-71.
22. Tanaka N, Fujioka A, Yamamura K, et al. Trifluorothymidine incorporation into DNA is the primary mechanism of action of TAS-102, and leads to markedly prolonged survival in a mouse model. In: 24th EORTC-NCI-AACR symposium 2012 (Abstract 66).
23. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008;8:180-92.
24. Yoshino T, Mizunuma N, Yamazaki K, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomized, placebo-controlled phase 2 trial. Lancet Oncol 2012;13:993-1001.
25. Fujita H, Miyadera K, Kato M, et al. TAS-115; a highly potent c-Met+VEGFRs dual inhibitor with prominent safety profile. In: American Association for Cancer Research Annual Meeting 2011 (Abstract 3577).
26. Ochiiwa H, Fujita H, Miyadera K, et al. The prominent safety profile of TAS-115, a novel c-Met+VEGFR dual kinase inhibitor can lead to potentiate the efficacy via durable inhibitor of angiogenesis. In: American Association for Cancer Research Annual Meeting 2011 (Abstract 3600).
27. Fujita H, Kato M, Miyadera K, et al. MET/VEGFR dual inhibition and prominent safety profiles of TAS-115 are favorable for the combination with chemotherapeutic drugs. In: American Association for Cancer Research Annual Meeting 2012 (Abstract 1785).
28. Sootome H, Masuko N, Ishihara K, Mitsuya M, Hirai H, Utsugi T. Highly potent and selective Aurora A inhibitor, TAS-2104 enhanced antitumor activity of taxanes in vitro. In: 24th EORTC-NCI-AACR symposium 2012 (Abstract 251).
29. Ishihara K, Masuko N, Sootome H, et al. TAS-2104, a highly potent and effective Aurora A inhibitor, enhanced antitumor activity of taxanes in vivo. In: 24th EORTC-NCI-AACR symposium 2012 (Abstract 252).
30. Abe T, Ichikawa K, Fujita R, et al. Characterization of TAS-117, a novel, highly potent and selective inhibitor of AKT. In: 24th EORTCNCI- AACR symposium 2012 (Abstract 356).
31. Ichikawa K, Abe T, Fukushima H, et al. A novel highly potent AKT inhibitor TAS-117 demonstrated synergistic antitumor activity in combination with paclitaxel through enhancement of apoptosis induction. In: 24th EORTC-NCI-AACR symposium 2012 (Abstract 5).
32. Sootome H, Fujita H, Ochiiwa H, et al. Identification & biological characterization of a highly potent, irreversible inhibitor of FGFR, TAS-2985. In: 24th EORTC-NCI-AACR symposium 2012 (Abstract 380).
33. Nakatsuru Y, Fujita H, Sootome H, et al. Significant in vivo antitumor activity by a highly potent, irreversible FGFR Inhibitor, TAS-2985. In: 24th EORTC-NCI-AACR symposium 2012 (Abstract 383).
34. Miyadera K, Kato M, Takahashi I, et al. TAS-2913 is a mutant selective EGFR inhibitor for NSCLC: characterization against EGFR T790M in cell and xenograft models. In: 24th EORTC-NCI-AACR symposium 2012 (Abstract 142).
35. Okubo S, Muraoka H, Kanoh A, et al. TAS-116, a novel, orally bioavailable HSP90a/β selective inhibitor demonstrates highly potent antitumor activity in preclinical models with a favorable PK profile. In: 24th EORTC-NCI-AACR symposium 2012 (Abstract 291).
36. Yoshimura C, Kitade M, Oshiumi H, et al. Evolution of highly selective HSP90a/β inhibitors with unique binding mode. In: 24th EORTC-NCIAACR symposium 2012 (Abstract 292).
37. Kodama Y, Hitotsumachi H, Shibata Y, et al. TAS-116, a novel, orally bioavailable highly potent HSP90a/β selective inhibitor demonstrates favorable tissue distribution properties which lead to minimized ocular toxicity. In: 24th EORTC-NCI-AACR symposium 2012 (Abstract 290).